Clinical trials
Leukemia clinical trials
Cancer of the blood and bone marrow that affects how blood cells are made. We’re tracking 1,284 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05736965RecruitingPhase 2
Selinexor with azacitidine and venetoclax for new AML
This trial studies whether selinexor combined with azacitidine and venetoclax can treat newly diagnosed acute myeloid leukemia (AML) in people who may not be able to tolerate intensive chemotherapy. It’s aimed at improving leukemia control with a treatment approach designed for patients with higher risk from other health problems.
ChangzhouAges 18 years+ - NCT05805098RecruitingPhase 2/Phase 3
Testing Venetoclax with chemo for newly diagnosed AML
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
Suzhou, JiangsuAges 18–60 - NCT05840575Recruiting
Study of thinking changes in young people during cancer treatment
This study looks at how thinking and memory may change in children and young adults after a new cancer diagnosis, especially around chemotherapy. It may help doctors better understand and track brain-related side effects early.
CopenhagenAges 7–29 - NCT05909293Recruiting
Venetoclax maintenance for older adults with AML in remission
This study tests whether “maintenance” treatment with venetoclax can help older adults with acute myeloid leukemia (AML) stay in remission after initial therapy. It may help delay the return of AML, especially in people who achieved first complete remission.
Nanjing, JiangsuAges 60–85 - NCT06045091RecruitingEarly Phase 1
BCMA-targeted CAR-NK cells for multiple myeloma or plasma cell leukemia
This trial tests an experimental therapy using immune cells (CAR-NK cells) designed to target and kill cancer cells in people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to treatment. The goal is to see if it is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04908228RecruitingPhase 2
Fixed treatment with ibrutinib and obinutuzumab for untreated CLL
This Phase 2 study tests a fixed-length treatment plan using ibrutinib plus obinutuzumab for people with newly diagnosed, active CLL/SLL that needs treatment. It may help control the leukemia/lymphoma by combining a targeted drug with an antibody therapy.
Milan, MIAges 18 years+ - NCT05328258RecruitingPhase 3
Triptorelin to help protect fertility during cancer chemotherapy
This Phase 3 study tests whether a hormone medicine called triptorelin (a GnRH “fertility-protecting” medicine) can better protect ovarian function while you receive chemotherapy. The goal is to help preserve fertility and reduce the risk of early ovarian failure from cancer treatment.
GothenburgAges 14–42 - NCT05694312RecruitingPhase 2
Ibrutinib for anemia caused by immune destruction in CLL/SLL
This Phase 2 trial tests ibrutinib, a prescription medicine, to treat active autoimmune hemolytic anemia (AIHA) in people with CLL/SLL or a CLL-like condition. It may help reduce anemia when steroids don’t work well, don’t last, or are needed too long.
FlorenceAges 18 years+ - NCT05788679RecruitingPhase 2
Use a patient’s genetic test to guide treatment after transplant
This study looks at a personalized lab test to detect small amounts of disease after a stem cell transplant and then decide what treatment comes next. It may help some people with certain bone-marrow diseases stay in remission while avoiding unnecessary treatment.
StockholmAges 18 years+ - NCT05245487Recruiting
Study of blood samples in older people with relapsed lymphoma
This study looks at blood (“hematopoietic”) information in people age 60+ with relapsed B-cell non-Hodgkin lymphoma who need an additional round of treatment. It may help researchers understand changes in the body during active lymphoma therapy.
CopenhagenAges 60 years+ - NCT04897490Recruiting
Real-world study of ATO plus ATRA for adult acute APL
This study looks at how well first-time treatment with ATO plus ATRA works in adults with acute promyelocytic leukemia (APL). It mainly checks treatment results in real life, including whether patients reach “molecular remission” (very deep disease control).
La Plata, Buenos AiresAges 18 years+ - NCT05127148Recruiting
Real-world study of pediatric-like treatment for Ph-negative ALL
This study follows how well a “pediatric-style” treatment plan works in teens and young adults with Ph-negative acute lymphoblastic leukemia (ALL) in real-world care. It mainly aims to understand outcomes and safety for patients who fit the specific leukemia and health criteria.
Paraná, Entre Ríos ProvinceAges 18–40 - NCT06211166Recruiting
Tracking cancer genes after stem cell transplant with digital PCR
This trial uses a precise blood test called digital PCR to measure tiny amounts of leftover cancer cells in patients who have had a stem cell transplant. It helps doctors see how well the transplant is working and if more treatment is needed.
Beijing, Beijing MunicipalityAges Any age - NCT06220487RecruitingPhase 2
New drug combo for Ph+ ALL without transplant
This trial tests a combination of three drugs—olverembatinib, a bispecific T-cell engager, and chidamide—for adults newly diagnosed with Ph+ ALL who cannot have a stem cell transplant. The goal is to see if this treatment works well without needing intensive chemotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT07874451Recruiting
Study of BCL-2 inhibitor treatments for chronic lymphocytic leukemia
This study looks at real-world experiences of people with chronic lymphocytic leukemia (CLL) who have used or are using a type of targeted therapy called a BCL-2 inhibitor. It aims to understand how well these treatments work and their side effects in everyday practice.
Nanjing, JiangsuAges 18 years+ - NCT06232694Recruiting
Combination therapy for newly diagnosed AML
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Nanjing, JiangsuAges 18–60 - NCT06250595Recruiting
European rare blood disorder registry
This study is building a registry of people with rare blood diseases. By joining, you help doctors learn more about these conditions and improve future care.
Barcelona, CataloniaAges Up to 100 years - NCT06256627Recruiting
Maintenance treatment of 'ITIVA' for AML in remission
This trial tests a maintenance treatment called 'ITIVA' for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy and consolidation therapy. The goal is to see if this treatment helps keep the leukemia from coming back.
Zhengzhou, HenanAges 14 years+ - NCT06046313RecruitingPhase 2
Low-dose decitabine plus venetoclax for older AML/MDS
This trial tests a combination of two drugs (decitabine and venetoclax) at a very low, extended dose for people aged 60 or older who have been newly diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if this gentler approach is effective and well-tolerated.
Hangzhou, ZhejiangAges 60 years+ - NCT06328179Recruiting
VHEA treatment for leukemia with KMT2A gene changes
This trial tests a combination treatment (VHEA) for adults with newly diagnosed or relapsed acute myeloid leukemia (AML) that has a specific genetic change called KMT2A. It aims to see if this treatment is safe and effective for patients who meet certain health requirements.
Huai'an, JiangsuAges 18–60 - NCT06336395RecruitingPhase 2
ALL treatment study for people under 41
This trial tests a treatment plan for people with a certain type of acute lymphoblastic leukemia (ALL) called B-lineage ALL. It aims to see how well the treatment works and how safe it is.
Kuala LumpurAges Up to 40 years - NCT06355739Recruiting
CAR T cells for children with relapsed B-cell leukemia
This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.
Tianjin, Tianjin MunicipalityAges 3–18 - NCT06345365RecruitingPhase 3
MA+AZA for Newly Diagnosed AML
This trial tests a combination of two medicines (called MA+AZA) for people who have just been diagnosed with acute myeloid leukemia (AML). It aims to see if this treatment can help control the disease and improve outcomes.
Zhengzhou, HenanAges 18–75 - NCT06381817RecruitingPhase 3
Stem cell transplant comparison for T-cell leukemia
This study compares two types of stem cell transplants for adults with T-ALL: one using a half-matched donor alone, and one using a half-matched donor plus umbilical cord blood. The goal is to see which approach gives better results with fewer side effects.
Suzhou, JiangsuAges Any age
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia?
- Yes. Clin2 currently lists 1,284 recruiting leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.